Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Efficacy Of Sotrovimab On Omicron Ba.2, Ba.4 And Ba.5 Subvariants Of Sars-cov-2 Vs. Other Early Therapies: A Systematic Review And Meta-analysis Of Literature Data.

Home
Efficacy Of Sotrovimab On Omicron Ba.2, Ba.4 And Ba.5 Subvariants Of Sars-cov-2 Vs. Other Early Therapies: A Systematic Review And Meta-analysis Of Literature Data.

Related Experiment Video

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a

Antonio Russo¹, Pierantonio Grimaldi¹, Mariantonietta Pisaturo¹

¹Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy.

Frontiers in Immunology

|February 14, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Keywords:

COVID-19 early treatment hospitalization monoclonal antibodies mortality

More Related Videos

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Related Experiment Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Sotrovimab did not significantly reduce COVID-19 hospitalization or mortality in Omicron BA.2, BA.4, and BA.5 subvariants compared to other antivirals. This meta-analysis found no statistical difference in outcomes for high-risk patients.

Area of Science:

Infectious Diseases
Virology
Clinical Pharmacology

Background:

Evaluating sotrovimab's efficacy against COVID-19 Omicron BA.2, BA.4, and BA.5 subvariants.
Comparing sotrovimab to other antivirals for high-risk COVID-19 patients.
Assessing impact on hospitalization and mortality rates.

Approach:

Systematic review and meta-analysis of RCTs and observational studies.
Searched MEDLINE, Google Scholar, and Cochrane Library adhering to PRISMA guidelines.
Included four studies with 8,041 patients.

Key Points:

Meta-analysis revealed no statistically significant difference in hospitalization or mortality between sotrovimab and other treatments.
Relative Risk (RR) for mortality: OR 0.38, 95% CI 0.10-1.49, p=0.166.

Hospitalization rate: OR 1.66, 95% CI 0.41-6.66, p=0.477.

Conclusions:

Sotrovimab demonstrated no significant advantage over other antivirals in preventing COVID-19 progression, hospitalization, or mortality.
Findings apply to patients with high risk of progression during Omicron BA.2, BA.4, and BA.5 waves.
Further research may be needed to clarify optimal antiviral strategies.